Natriuretic peptides in heart failure;Péptidos natriuréticos en insuficiencia cardiaca

Revista Espanola de Cardiologia Suplementos

Volumn 6, Issue F, 2006, Pages

  Almenar Bonet, Luis ^a   Martínez Dolz, Luis ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Heart failure; Natriuretic peptides

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; BIOLOGICAL MARKER;

BIOCHEMISTRY; CLINICAL PRACTICE; COMORBIDITY; DIAGNOSTIC ERROR; DIURETIC ACTIVITY; DYSPNEA; HEART FAILURE; HORMONE BLOOD LEVEL; HORMONE RELEASE; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; LUNG DISEASE; MONITORING; NONHUMAN; OBESITY; PHYSIOLOGY; PROGNOSIS; REVIEW; SCREENING; VASODILATATION; CONGESTIVE HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; METABOLISM; SUDDEN DEATH;

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; DEATH, SUDDEN, CARDIAC; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; LUNG DISEASES; MYOCARDIUM; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; NATRIURETIC PEPTIDES; OBESITY; PROGNOSIS; RENAL INSUFFICIENCY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34250683403     PISSN: 11313587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1131-3587(06)74831-2     Document Type: Article

References (71)

1. De Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981;28:89-94.
2. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clinical Chemistry. 2004;50:33-50.
3. Valli N, Gobinet A, Bordenave L. Review of 10 years of the clinical use of brain natriuretic peptide in cardiology. J Lab Clin Med. 1999;134:437-44.
4. Yandle TG. Biochemistry of natriuretic peptides. J Intern Med. 1994;235:561-76.
5. Hall C, Aaberge L, Stokke O. In vitro stability of N-terminal proatrial natriuretic factor in unfrozen samples: an important prerequisite for its use as a biochemical parameter of atrial pressure in clinicl routine. Circulation. 1995;91:911-2.
6. Davidson NC, Coutie WJ, Struthers AD. N-terminal proatrial natriuretic petide and brain natriuretic peptide are stable for up to 6 hours in whole blood in vitro. Circulation. 1995;91:1276-7.
7. Maack T, Suzuki M, Almeida FA, Nussenzveig D, Scarborough RM, McEnroe GA et al. Physiological role of silent receptors of atrial natriuretic factor. Science. 1987;238:675-8.
8. McDovell G, Patterson C, Maguire S, Shaw C, Nicholls DP, Hall C. Variability of NT-proANP and C-ANP. Eur J Clin Invest. 2002;32:545-8.
9. Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocrine Rev. 2003;24:341-56.
10. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clinical Chemistry. 2004;50:33-50.
11. Hunt PJ, Yandle TG, Nicholls MG, Richards AM, Espiner EA. The amino-terminal portion of pro-brain natriuretic peptide (ProBNP) circulates in human plasma. Biochem Biophys Res Commun. 1995;214:1175-83.
12. Hunt PJ, Richards AM, NichoJls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-proBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf). 1997;47:287-96.
13. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med. 2001;39:571-88.
14. Murdoch DR, Byrne J, Farmer R, Morton JJ. Disparity between studies of the stability of BNP in blood: comparison of endogenous and exogenous peptide. Heart. 1999;81:212-3.
15. McNairy M, Gardetto N, Clopton P, García A, Krishnaswamy P, Kazanegra R et al. Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide. Am Heart J. 2002;143:406-11.
16. Cheung BM, Dickerson JE, Ashby MJ, Brown MJ, Brown J. Effects of physiological increments in human alpha-atrial natriuretic peptide and human brain natriuretic peptide in normal male subjects. Clin Sci (Lond). 1994;86:723-30.
17. Lang CC, Motwani JG, Coutie WJ, Struthers AD. Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism. Clin Sci (Colch). 1992;82:619-23.
18. Ogawa Y, Nakao K, Mukoyama M, Hosoda K, Shirakami G, Arai H, et al. Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide. Circ Res. 1991;69:491-500.
19. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of Btype natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:95-203.
20. Kalra PR, Clague JR, Bolger AP, Anker SD, Poole-Wilson PA, Struthers AD, et al. Myocardial production of C-type natriuretic peptides in chronic heart failure. Circulation. 2003;107:571-3.
21. Lang RE, Thölken H, Ganten D, Luft FC, Ruskoaho H, Unger T. Atrial natriuretic factor-a circulating hormone stimulated by volume loading. Nature. 1985;314:264-6.
22. Ruskoaho H. Tholken H, Lang R. Increase in atrial pressure releases atrial natriuretic peptide from isolated perfused rat hearts. Pfluegers Arch. 1986;407:170-4.
23. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA. 2002;288:1252-9.
24. Franco V, Chen YF, Oparil S, Feng JA, Wang D, Hage F, et al. Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling. Hypertension. 2004;44:746-50.
25. Yasue H, Obata K, Okumura K, Kurose M, Ogawa H, Matsuyama K, et al. Increased secretion of atrial natriuretic polypeptide from the left ventricle in patients with dilated cardiomyopathy. J Clin Invest. 1989;83:46-54.
26. Mukoyama M, Nakao K, Saito Y, Ogawa Y, Hosoda K, Suga S, et al. Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med. 1990;323:757-8.
27. Wei CM, Heutlein DM, Perrela MA, Lerman A, Rodeheffer RJ, McGregor CGA, et al. Natriuretic peptide system in human heart failure. Circulation. 1993;88:1004-9.
28. Nakao K, Ogawa Y, Suga SI, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. J Hypertens. 1992;10:907-12.
29. Ruskoaho H. Atrial natriuretic peptide: síntesis, release, and metabolism. Pharmacol Rev. 1992;44:479-602.
30. De Bold AJ, Bruneau BG, Kuroski ML. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovas Res. 1996;31:7-18.
31. Inoue S, Murakami Y, Sano K, Katoh H, Shimada T. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail. 2000;6:92-6.
32. Mäntymaa P, Vuolteenaho O, Marttila M, Ruskoaho H. Atrial strech induces rapid increase in brain natriuretic peptide but not in atrial natriuretic peptide gene expresión in vitro. Endocrinology. 1993;133:1470-3.
33. Lang CC, Coutie WJ, Khong TK, Choy AM, Struthers AD. Dietary sodium loading increases plasma brain natriuretic peptide levels in man. J Hypertens. 1991;9:779-82.
34. Buckley MG, Markandu ND, Sagnella GA, McGregor GA. Brain and atrial natriuretic peptides: a dual peptide system of potential importance in sodium balance and blood pressure regulation in patients with essential hypertension. J Hypertens. 1994;12:809-13.
35. Ogawa T, Linz W, Stevenson M, Bruneau BG, Kuroski ML, Chen JH, et al. Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production. Circulation. 1996;93:2059-67.
36. Tokola H, Hautala N, Marttila M, Magga J, Pikkarainen S, Kerkela R, et al. Mechanical load-induced alterations in B-type natriuretic peptide gene expression. Can J Physiol Pharmacol. 2001;79:646-53.
37. Silver MA, Maisel A, Yancy CW, McCullough PA, Burnett JC, Francis GS, et al. BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Heart Failure. 2004;10 Suppl 3:1-30.
38. Maisel A, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergengy diagnosis of heart failure. N Engl J Med. 2002;347:161-7.
39. Maisel A, Hollander J, Guss D, McCullough P, Nowak R, Green G, et al. Primary results of the rapid emergency department heart failure outpatients trial (REDHOT). J Am Coll Cardiol. 2004;44:1334-6.
40. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350:647-54.
41. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35:681-9.
42. Akiba T, Tachibana K, Togaski K, Hiroe M, Marumo F. Plasma human brain natriuretic peptide in chronic renal failure. Clin Nephrol. 1995;44 Suppl 1:S61-4.
43. National Kidney Foundation. Clinical practice guidelins for chronic kidney disease: evaluation, classification and stratification. Am J Kid Disease. 2002; 2 Suppl 1:S46-75.
44. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide (BNP) assay in differentiating HF from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 2002;39:202-9.
45. Berman B, Spragg R, Maisel A. B-type natriuretic peptide (BNP) levels in differentiating congestive heart failure from acute respiratory distress syndrome (ARDS). Circulation. 2002;106:191.
46. Sarzani R, Dessi-Fulgheri P, Paci VM, Espinosa E, Rappelli A. Expresión of natriuretic peptide receptors un human adipose and other tisúes. J Endocrinol Invest. 1996;19:581-5.
47. Sengenes C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J. 2000;14:1345-51.
48. Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO, Harris BC, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol. 2004;43:1590-5.
49. Rivera M, Talens R, Salvador A, Bertomeu V, Miró V, García de Burgos F, et al. Grupo Disfunción VI Comunidad Valenciana. NT-proBNP e hipertensión. Su importancia en el diagnóstico de insuficiencia cardíaca. Rev Esp Cardiol. 2004;57:396-402.
50. Rivera M, Talens R, Salvador A, Bertomeu V, Miró V, Jordán A, et al. Grupo de disfunción VI Comunidad Valenciana. Ventricular hypertrophy increases NT-proBNP in subjects with and without hypertension. Int J Cardiol. 2004;96:265-71.
51. Osca J, Quesada A, Arnau MA, Osa A, Hervás I, Almenar L, et al. Péptido cerebral natriurético. Valor diagnóstico en la insuficiencia cardiaca. Rev Esp Cardiol. 2002;55:7-15.
52. Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P, et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction: results from the Breathing Not Properly (BNP) multinational study. J Am Coll Cardiol. 2003;41:2010-7.
53. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation. 2002;105:595-601.
54. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:358-9.
55. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107:1278-83.
56. Bettencourt P, Ferreira S, Azevedo A, Ferreira A. Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcomes after hospital discharge in patients with heart failure. Am J Med. 2002;113:215-9.
57. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002;105:2392-7.
58. Bradley DJ, Bradley EA, Baughman KL, Berger RD, Calkins H, Goodman SN, et al. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trial. JAMA. 2003;289:730-40.
59. Sinha AM, Filzmaier K, Breithardt OA, Kunz D, Graf J, Markus KU, et al. Usefulnessof brain natriuretic release as a surrogate marker of the efficacy of long-term cardiac resynchronization theraphy in patients with heart failure. Am J Cardiol. 2003;91:755-8.
60. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA. 2002;288:1252-9.
61. Silver MA, Pisano C. High incidence of elevated B-type natriuretic peptide levels and risk factors for heart failure in an unselected at-risk population (stage A): implications for heart failure screening programs. Congest Heart Fail. 2003;9:127-32.
62. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, et al. Value of natriuretic peptides in assessment of patiens with possible new heart failure in primary care. Lancet. 1997;350:1349-53.
63. Burgess MI, Bhattacharyya A, Ray SG. Echocardiography after cardiac transplantation. J Am Soc Echocardiogr. 2002;15:917-25.
64. Mehra MR, Uber PA, Potluri S, Ventura HO, Scott RL, Park MH. Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation. Am J Cardiol. 2004;94:454-8.
65. Arnau MA, Almenar L, Hervás I, Osa A, Martínez-Dolz L, Rueda J, et al. Predictive value of brain natriuretic peptide in the diagnosis of heart transplant rejection. J Heart Lung Transplant. 2004;23:850-6.
66. Sodian R, Loebe M, Schmitt C, Potapov EV, Siniawski H, Muller J, et al. Decreased plasma concentrations of brain natriuretic peptide as a potential indicator of cardiac recovery in patients supported by mechanical circulatory assist systems. J Am Coll Cardiol. 2001;38:1942-9.
67. Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol. 2001;37:1781-7.
68. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126-30.
69. Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponina I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality in advanced heart failure. Circulation. 2003;108:833-8.
70. Yancy CW.Treatment with B-type natriuretic peptide for chronic decompensated heart failure: insights learned from the follow-up serial infusion of nesiritide (FUSION) trial. Heart Fail Rev. 2004;9:209-16.
71. Topol EJ. Nesiritide: not verified. N Engl J Med. 2005;353:113-6.